PressMarch 4, 2022 Magellan Rx Management Releases Clinical Insights on the Use of Psychedelics in Treating Mental Health Conditions
PressMarch 4, 2022 Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research
PressFebruary 25, 2022 HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research
PressFebruary 24, 2022 COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
PressFebruary 23, 2022 PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma
PressFebruary 22, 2022 World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
PressFebruary 18, 2022 Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules
PressFebruary 17, 2022 Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
PressFebruary 15, 2022 BetterLife Lead Drug BETR-001 Promotes Structural Neural Plasticity in Preclinical Model
PressFebruary 14, 2022 Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19
PressFebruary 12, 2022 HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market
PressFebruary 10, 2022 Elemental Advisors Launches PSYK ETF Focused on the Medical Psychedelics Industry
PressFebruary 9, 2022 Ehave Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California Based Rejuv IV
PressFebruary 8, 2022 Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada
PressFebruary 4, 2022 Tryp Therapeutics Announces $2,000,000 Financing and Changes in Management, Board of Directors
